Abstract
The previously developed ASILV model for calculating epidemic spread under conditions of lockdown and mass vaccination was modified to analyse the intensity of COVID-19 infection growth in the allocated age groups.
Comparison of the results of calculations of the epidemic spread, as well as the values of the seven-day incidence values with the corresponding observation data, shows their good correspondence for each of the selected age groups.
The greatest influence on the overall spread of the epidemic is in the 20-40 age groups. The relatively low level of vaccination and the high intensity of contact in these age groups contributes to the emergence of new waves of the epidemic, which is especially active when the virus mutates and the lockdown conditions are relaxed.
The intensity of the epidemic in the 90+ age group has some peculiarities compared to other groups, which may be explained by differences in contact patterns among individuals in this age group compared to others.
Approximate ratios for estimating mortality as a function of the intensity of infection for individual age groups are provided.
The proposed stratified ASILV model by age group will allow more detailed and accurate prediction of the spread of the COVID-19 epidemic, including when new, more transmissible versions of the virus mutate and emerge.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Husmann.rus
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
statement regarding the availability of all data referred to in the manuscript